| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oligodeoxyribonucleotides | 130 | 2020 | 245 | 10.520 |
Why?
|
| CpG Islands | 94 | 2011 | 216 | 8.930 |
Why?
|
| Adjuvants, Immunologic | 90 | 2021 | 227 | 7.530 |
Why?
|
| Toll-Like Receptor 9 | 46 | 2025 | 211 | 4.820 |
Why?
|
| DNA, Bacterial | 37 | 2010 | 267 | 3.720 |
Why?
|
| B-Lymphocytes | 48 | 2007 | 572 | 2.930 |
Why?
|
| Oligonucleotides | 28 | 2022 | 221 | 2.500 |
Why?
|
| Lymphocyte Activation | 47 | 2013 | 758 | 2.130 |
Why?
|
| DNA | 31 | 2009 | 838 | 2.060 |
Why?
|
| Autoimmunity | 12 | 2025 | 237 | 2.020 |
Why?
|
| Oligonucleotides, Antisense | 16 | 2022 | 144 | 2.020 |
Why?
|
| Dinucleoside Phosphates | 21 | 2008 | 32 | 1.980 |
Why?
|
| Immunity, Innate | 26 | 2017 | 797 | 1.950 |
Why?
|
| Receptors, Cell Surface | 20 | 2005 | 429 | 1.910 |
Why?
|
| Toll-Like Receptor 7 | 12 | 2025 | 103 | 1.910 |
Why?
|
| Interferon-alpha | 18 | 2025 | 103 | 1.680 |
Why?
|
| Toll-Like Receptor 8 | 10 | 2025 | 49 | 1.670 |
Why?
|
| Animals | 195 | 2025 | 20695 | 1.650 |
Why?
|
| Mice | 149 | 2020 | 10848 | 1.530 |
Why?
|
| Th1 Cells | 25 | 2008 | 173 | 1.460 |
Why?
|
| Membrane Glycoproteins | 20 | 2012 | 669 | 1.400 |
Why?
|
| Cytokines | 36 | 2011 | 934 | 1.390 |
Why?
|
| Immunotherapy | 13 | 2025 | 256 | 1.310 |
Why?
|
| Dendritic Cells | 29 | 2008 | 525 | 1.310 |
Why?
|
| Cancer Vaccines | 17 | 2013 | 49 | 1.270 |
Why?
|
| NF-kappa B | 16 | 2006 | 469 | 1.250 |
Why?
|
| Lupus Erythematosus, Systemic | 13 | 2007 | 168 | 1.240 |
Why?
|
| Neoplasms | 14 | 2025 | 1371 | 1.210 |
Why?
|
| Vaccines, DNA | 18 | 2010 | 98 | 1.160 |
Why?
|
| Interleukin-12 | 26 | 2008 | 128 | 1.120 |
Why?
|
| DNA-Binding Proteins | 18 | 2010 | 1185 | 1.070 |
Why?
|
| Thionucleotides | 17 | 2011 | 38 | 1.070 |
Why?
|
| Mice, Inbred BALB C | 48 | 2013 | 883 | 1.010 |
Why?
|
| Base Sequence | 44 | 2010 | 1330 | 1.000 |
Why?
|
| Antineoplastic Agents | 12 | 2012 | 661 | 0.980 |
Why?
|
| Vaccines | 7 | 2009 | 98 | 0.930 |
Why?
|
| Muscular Dystrophy, Duchenne | 2 | 2016 | 41 | 0.930 |
Why?
|
| Interferon-gamma | 36 | 2013 | 567 | 0.920 |
Why?
|
| Toll-Like Receptors | 14 | 2008 | 431 | 0.910 |
Why?
|
| Autoimmune Diseases | 12 | 2008 | 229 | 0.840 |
Why?
|
| T-Lymphocytes | 27 | 2021 | 1010 | 0.780 |
Why?
|
| Humans | 130 | 2025 | 63643 | 0.770 |
Why?
|
| Melanoma | 8 | 2025 | 331 | 0.740 |
Why?
|
| Signal Transduction | 19 | 2010 | 3031 | 0.730 |
Why?
|
| Lipopolysaccharides | 13 | 2005 | 624 | 0.720 |
Why?
|
| Immunity, Cellular | 12 | 2020 | 178 | 0.720 |
Why?
|
| Apoptosis | 13 | 2003 | 1079 | 0.700 |
Why?
|
| Cells, Cultured | 38 | 2010 | 2158 | 0.700 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2025 | 448 | 0.640 |
Why?
|
| Leukocytes, Mononuclear | 13 | 2008 | 243 | 0.630 |
Why?
|
| Morpholinos | 2 | 2016 | 52 | 0.630 |
Why?
|
| Mitogen-Activated Protein Kinases | 6 | 2003 | 217 | 0.610 |
Why?
|
| Killer Cells, Natural | 17 | 2008 | 217 | 0.610 |
Why?
|
| Reference Standards | 1 | 2019 | 73 | 0.600 |
Why?
|
| Dystrophin | 2 | 2016 | 31 | 0.580 |
Why?
|
| DNA, Viral | 5 | 2010 | 232 | 0.570 |
Why?
|
| DNA, Single-Stranded | 1 | 2019 | 106 | 0.560 |
Why?
|
| Nucleic Acids | 1 | 2019 | 60 | 0.560 |
Why?
|
| Chemokines, CXC | 6 | 2007 | 29 | 0.550 |
Why?
|
| Exons | 2 | 2016 | 199 | 0.550 |
Why?
|
| Lymphoma, B-Cell | 9 | 2007 | 61 | 0.550 |
Why?
|
| Autoantigens | 3 | 2007 | 137 | 0.540 |
Why?
|
| DNA Methylation | 6 | 2001 | 292 | 0.530 |
Why?
|
| Vaccination | 10 | 2012 | 364 | 0.530 |
Why?
|
| Th2 Cells | 9 | 2008 | 98 | 0.520 |
Why?
|
| Mice, Inbred C57BL | 41 | 2015 | 3398 | 0.520 |
Why?
|
| Drug Approval | 1 | 2016 | 26 | 0.510 |
Why?
|
| Cell Division | 13 | 2004 | 450 | 0.500 |
Why?
|
| Monocytes | 7 | 2004 | 354 | 0.500 |
Why?
|
| Antibody Formation | 8 | 2007 | 114 | 0.490 |
Why?
|
| Asthma | 7 | 2009 | 466 | 0.480 |
Why?
|
| Spleen | 21 | 2006 | 483 | 0.470 |
Why?
|
| Communicable Diseases | 4 | 2012 | 90 | 0.470 |
Why?
|
| Immunization | 6 | 2020 | 133 | 0.470 |
Why?
|
| Retroviridae | 7 | 1994 | 74 | 0.470 |
Why?
|
| Nuclear Proteins | 3 | 2010 | 778 | 0.460 |
Why?
|
| Leukocytes | 4 | 2007 | 103 | 0.460 |
Why?
|
| Cell Line | 23 | 2013 | 2040 | 0.460 |
Why?
|
| Macrophages | 10 | 2013 | 1041 | 0.450 |
Why?
|
| Influenza, Human | 1 | 2017 | 208 | 0.450 |
Why?
|
| Interleukin-6 | 9 | 2008 | 320 | 0.440 |
Why?
|
| Liver Neoplasms | 4 | 2023 | 300 | 0.440 |
Why?
|
| Tumor Necrosis Factor-alpha | 14 | 2008 | 616 | 0.440 |
Why?
|
| Mice, Knockout | 21 | 2020 | 2110 | 0.430 |
Why?
|
| Muramidase | 4 | 2004 | 46 | 0.430 |
Why?
|
| Female | 82 | 2025 | 33026 | 0.430 |
Why?
|
| CD8-Positive T-Lymphocytes | 12 | 2013 | 677 | 0.430 |
Why?
|
| T-Lymphocytes, Cytotoxic | 9 | 2008 | 181 | 0.410 |
Why?
|
| Listeriosis | 3 | 2003 | 30 | 0.390 |
Why?
|
| Hypersensitivity | 7 | 2012 | 65 | 0.390 |
Why?
|
| Mice, Inbred DBA | 15 | 2002 | 84 | 0.380 |
Why?
|
| Molecular Sequence Data | 21 | 1999 | 1992 | 0.360 |
Why?
|
| Bacterial Vaccines | 3 | 2013 | 78 | 0.350 |
Why?
|
| Antiviral Agents | 4 | 2013 | 322 | 0.350 |
Why?
|
| Antibodies, Anti-Idiotypic | 8 | 2005 | 33 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2019 | 864 | 0.340 |
Why?
|
| Immunity, Active | 3 | 2006 | 10 | 0.330 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 418 | 0.330 |
Why?
|
| Receptors, Antigen, B-Cell | 5 | 2003 | 60 | 0.330 |
Why?
|
| Tumor Cells, Cultured | 15 | 2006 | 456 | 0.330 |
Why?
|
| I-kappa B Proteins | 3 | 2001 | 39 | 0.330 |
Why?
|
| Transcription Factor AP-1 | 4 | 2003 | 41 | 0.320 |
Why?
|
| Genetic Therapy | 4 | 2001 | 791 | 0.310 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2008 | 212 | 0.310 |
Why?
|
| Drug Design | 2 | 2007 | 136 | 0.310 |
Why?
|
| Chemokine CXCL10 | 7 | 2007 | 56 | 0.310 |
Why?
|
| Flow Cytometry | 11 | 2008 | 663 | 0.310 |
Why?
|
| RNA, Small Interfering | 3 | 2012 | 921 | 0.300 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 2006 | 73 | 0.300 |
Why?
|
| Paclitaxel | 2 | 2008 | 101 | 0.300 |
Why?
|
| RNA, Viral | 9 | 2009 | 276 | 0.290 |
Why?
|
| Hematopoietic Stem Cells | 3 | 1996 | 282 | 0.290 |
Why?
|
| Leukemia Virus, Murine | 7 | 1995 | 30 | 0.290 |
Why?
|
| Antigens, T-Independent | 2 | 2005 | 10 | 0.290 |
Why?
|
| Immune System | 5 | 2010 | 130 | 0.280 |
Why?
|
| Cathepsins | 1 | 2008 | 34 | 0.280 |
Why?
|
| Bacteremia | 2 | 2006 | 94 | 0.280 |
Why?
|
| Inflammation | 8 | 2010 | 1147 | 0.280 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2007 | 21 | 0.270 |
Why?
|
| Autoantibodies | 2 | 2007 | 183 | 0.270 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1998 | 126 | 0.260 |
Why?
|
| Skin Neoplasms | 3 | 2025 | 410 | 0.260 |
Why?
|
| Interferon Type I | 7 | 2012 | 187 | 0.260 |
Why?
|
| Mice, Inbred C3H | 12 | 2005 | 176 | 0.260 |
Why?
|
| Male | 40 | 2025 | 30008 | 0.260 |
Why?
|
| RNA | 6 | 2012 | 425 | 0.260 |
Why?
|
| Neuroblastoma | 2 | 2006 | 53 | 0.250 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 12 | 2010 | 455 | 0.250 |
Why?
|
| Glanders | 1 | 2006 | 1 | 0.250 |
Why?
|
| Burkholderia mallei | 1 | 2006 | 1 | 0.250 |
Why?
|
| Lung | 6 | 2011 | 955 | 0.250 |
Why?
|
| Antigen Presentation | 8 | 2007 | 237 | 0.250 |
Why?
|
| Antigens, CD | 8 | 2011 | 347 | 0.250 |
Why?
|
| Neoplasm Proteins | 6 | 2008 | 281 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2003 | 57 | 0.240 |
Why?
|
| Germ-Free Life | 1 | 2005 | 8 | 0.240 |
Why?
|
| Chloroquine | 4 | 2003 | 61 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 1 | 2006 | 77 | 0.240 |
Why?
|
| RNA, Small Nuclear | 1 | 2005 | 25 | 0.240 |
Why?
|
| Gene Transfer Techniques | 3 | 2015 | 321 | 0.240 |
Why?
|
| Colonic Neoplasms | 3 | 2023 | 222 | 0.240 |
Why?
|
| Transcription Factors | 5 | 2002 | 1513 | 0.240 |
Why?
|
| Immunoglobulin G | 10 | 2004 | 460 | 0.230 |
Why?
|
| Dose-Response Relationship, Immunologic | 9 | 2012 | 50 | 0.230 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 456 | 0.230 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2001 | 16 | 0.220 |
Why?
|
| Diverticulitis, Colonic | 1 | 2025 | 35 | 0.220 |
Why?
|
| Gene Expression Regulation | 13 | 2006 | 1618 | 0.220 |
Why?
|
| Inosine | 1 | 2004 | 4 | 0.220 |
Why?
|
| Ribavirin | 1 | 2004 | 23 | 0.220 |
Why?
|
| Mink Cell Focus-Inducing Viruses | 5 | 1993 | 5 | 0.220 |
Why?
|
| Endosomes | 6 | 2015 | 177 | 0.210 |
Why?
|
| Immunoglobulin M | 6 | 2001 | 115 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 88 | 0.210 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2025 | 129 | 0.210 |
Why?
|
| Bone Marrow Transplantation | 4 | 2011 | 140 | 0.210 |
Why?
|
| Immunity, Mucosal | 4 | 2002 | 52 | 0.210 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2025 | 59 | 0.200 |
Why?
|
| Listeria monocytogenes | 1 | 2003 | 34 | 0.200 |
Why?
|
| In Vitro Techniques | 5 | 2019 | 490 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 237 | 0.200 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 2006 | 148 | 0.200 |
Why?
|
| Bacteria | 2 | 2003 | 306 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 9 | 2013 | 642 | 0.200 |
Why?
|
| Immunotherapy, Active | 1 | 2003 | 3 | 0.200 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2006 | 247 | 0.200 |
Why?
|
| Melioidosis | 3 | 2011 | 3 | 0.200 |
Why?
|
| Reactive Oxygen Species | 3 | 2000 | 224 | 0.200 |
Why?
|
| Drug Synergism | 7 | 2003 | 142 | 0.200 |
Why?
|
| Glutathione Disulfide | 1 | 2002 | 2 | 0.200 |
Why?
|
| Thymidine | 3 | 2004 | 25 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2023 | 48 | 0.200 |
Why?
|
| Immune Tolerance | 5 | 2009 | 179 | 0.190 |
Why?
|
| Hepatitis B Vaccines | 4 | 2005 | 14 | 0.190 |
Why?
|
| Radiosurgery | 1 | 2023 | 63 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2003 | 44 | 0.190 |
Why?
|
| Poly G | 1 | 2002 | 2 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 1999 | 104 | 0.190 |
Why?
|
| Vaccines, Synthetic | 5 | 2012 | 78 | 0.190 |
Why?
|
| Vaccinia virus | 2 | 2017 | 73 | 0.190 |
Why?
|
| Antigens, Neoplasm | 7 | 2006 | 135 | 0.190 |
Why?
|
| Immunoglobulin A | 2 | 2008 | 96 | 0.190 |
Why?
|
| Phosphates | 1 | 2003 | 93 | 0.190 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2000 | 46 | 0.190 |
Why?
|
| Transcription, Genetic | 9 | 2003 | 878 | 0.190 |
Why?
|
| Imidazoles | 5 | 2010 | 82 | 0.190 |
Why?
|
| Macrophage Activation | 5 | 2004 | 119 | 0.180 |
Why?
|
| Glycolates | 1 | 2001 | 3 | 0.180 |
Why?
|
| Time Factors | 10 | 2016 | 3770 | 0.180 |
Why?
|
| Rectal Neoplasms | 1 | 2023 | 115 | 0.180 |
Why?
|
| Malaria Vaccines | 3 | 2012 | 37 | 0.180 |
Why?
|
| Influenza Vaccines | 2 | 2004 | 99 | 0.180 |
Why?
|
| Robotic Surgical Procedures | 1 | 2025 | 160 | 0.180 |
Why?
|
| Transfection | 7 | 2006 | 694 | 0.180 |
Why?
|
| Interleukin-10 | 6 | 2004 | 160 | 0.180 |
Why?
|
| Oligoribonucleotides | 3 | 2011 | 15 | 0.180 |
Why?
|
| Lactoferrin | 1 | 2001 | 36 | 0.180 |
Why?
|
| Streptococcus agalactiae | 1 | 2001 | 79 | 0.180 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2002 | 337 | 0.180 |
Why?
|
| Tularemia | 2 | 2013 | 15 | 0.180 |
Why?
|
| Francisella tularensis | 2 | 2013 | 21 | 0.170 |
Why?
|
| Immunosuppressive Agents | 5 | 2003 | 379 | 0.170 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 4 | 2003 | 141 | 0.170 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2000 | 10 | 0.170 |
Why?
|
| Antigens, Bacterial | 3 | 2009 | 199 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 277 | 0.160 |
Why?
|
| Laparoscopy | 1 | 2025 | 494 | 0.160 |
Why?
|
| Injections, Subcutaneous | 7 | 2013 | 69 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 113 | 0.160 |
Why?
|
| Cell Proliferation | 7 | 2013 | 985 | 0.160 |
Why?
|
| Tissue Distribution | 3 | 2015 | 292 | 0.160 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2020 | 16 | 0.160 |
Why?
|
| Lymphocytes | 3 | 1996 | 202 | 0.160 |
Why?
|
| Adenoviridae | 2 | 2007 | 127 | 0.160 |
Why?
|
| Structure-Activity Relationship | 5 | 2015 | 374 | 0.160 |
Why?
|
| Immunization, Secondary | 1 | 1999 | 48 | 0.160 |
Why?
|
| Arthritis, Infectious | 1 | 1999 | 20 | 0.160 |
Why?
|
| Vertebrates | 1 | 2000 | 44 | 0.160 |
Why?
|
| Joints | 1 | 1999 | 33 | 0.160 |
Why?
|
| ErbB Receptors | 2 | 1997 | 115 | 0.150 |
Why?
|
| Bone Marrow | 3 | 1996 | 175 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2025 | 5711 | 0.150 |
Why?
|
| Lymphoma | 1 | 2020 | 104 | 0.150 |
Why?
|
| Animals, Newborn | 6 | 2010 | 239 | 0.150 |
Why?
|
| Peptides | 5 | 2011 | 574 | 0.150 |
Why?
|
| Adult | 19 | 2025 | 16902 | 0.150 |
Why?
|
| Chemokines | 5 | 2007 | 93 | 0.150 |
Why?
|
| Plasmodium yoelii | 3 | 2004 | 6 | 0.150 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 34 | 0.150 |
Why?
|
| Cyclosporine | 1 | 1998 | 77 | 0.150 |
Why?
|
| Histocompatibility Antigens Class II | 7 | 2013 | 182 | 0.140 |
Why?
|
| Enhancer Elements, Genetic | 2 | 1998 | 107 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 343 | 0.140 |
Why?
|
| Vaccinia | 1 | 2017 | 32 | 0.140 |
Why?
|
| Injections, Intraperitoneal | 5 | 2003 | 47 | 0.140 |
Why?
|
| Antigens | 5 | 2010 | 147 | 0.140 |
Why?
|
| Swine | 3 | 2008 | 389 | 0.140 |
Why?
|
| Viral Vaccines | 1 | 2017 | 54 | 0.130 |
Why?
|
| Neoplasms, Experimental | 3 | 2007 | 78 | 0.130 |
Why?
|
| Phosphorylation | 4 | 2003 | 936 | 0.130 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2009 | 59 | 0.130 |
Why?
|
| Walk Test | 1 | 2016 | 8 | 0.130 |
Why?
|
| Homeodomain Proteins | 1 | 1998 | 268 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1998 | 263 | 0.130 |
Why?
|
| Mice, Inbred Strains | 9 | 2003 | 189 | 0.130 |
Why?
|
| HIV Infections | 4 | 2008 | 972 | 0.130 |
Why?
|
| Burkholderia pseudomallei | 3 | 2011 | 3 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2007 | 53 | 0.130 |
Why?
|
| Middle Aged | 15 | 2025 | 17711 | 0.130 |
Why?
|
| HIV-1 | 4 | 2008 | 723 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 1998 | 345 | 0.130 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2006 | 182 | 0.130 |
Why?
|
| Kinetics | 7 | 2004 | 763 | 0.120 |
Why?
|
| Membrane Proteins | 3 | 2013 | 899 | 0.120 |
Why?
|
| Leukemia | 1 | 1996 | 60 | 0.120 |
Why?
|
| RNA, Messenger | 8 | 2008 | 1536 | 0.120 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 89 | 0.120 |
Why?
|
| Mitochondria | 1 | 1999 | 372 | 0.120 |
Why?
|
| Oleic Acids | 3 | 2008 | 6 | 0.120 |
Why?
|
| Cystic Fibrosis | 1 | 1997 | 121 | 0.120 |
Why?
|
| Mannitol | 3 | 2008 | 14 | 0.120 |
Why?
|
| Hepatitis B Surface Antigens | 6 | 2005 | 18 | 0.120 |
Why?
|
| Klebsiella Infections | 2 | 2007 | 22 | 0.120 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1995 | 15 | 0.120 |
Why?
|
| Cattle | 7 | 2008 | 311 | 0.120 |
Why?
|
| Peptide Fragments | 4 | 2008 | 410 | 0.120 |
Why?
|
| Aged | 12 | 2025 | 14524 | 0.120 |
Why?
|
| Mice, Transgenic | 4 | 2015 | 1276 | 0.120 |
Why?
|
| Apolipoprotein C-III | 1 | 2015 | 5 | 0.120 |
Why?
|
| Apolipoproteins B | 1 | 2015 | 19 | 0.120 |
Why?
|
| Enzyme Inhibitors | 4 | 2004 | 373 | 0.120 |
Why?
|
| Caco-2 Cells | 1 | 1995 | 70 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2002 | 149 | 0.120 |
Why?
|
| Cell Communication | 3 | 2006 | 130 | 0.120 |
Why?
|
| Malaria | 3 | 2003 | 148 | 0.120 |
Why?
|
| Antigen-Presenting Cells | 3 | 2008 | 178 | 0.120 |
Why?
|
| Recombinant Proteins | 6 | 2012 | 704 | 0.120 |
Why?
|
| Dimerization | 1 | 2015 | 145 | 0.120 |
Why?
|
| Cholesterol | 2 | 1995 | 259 | 0.120 |
Why?
|
| Polymethacrylic Acids | 1 | 2015 | 10 | 0.120 |
Why?
|
| Pneumonia, Bacterial | 2 | 2007 | 89 | 0.120 |
Why?
|
| Escherichia coli | 6 | 2001 | 707 | 0.120 |
Why?
|
| Disease Models, Animal | 10 | 2017 | 2196 | 0.120 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1995 | 17 | 0.110 |
Why?
|
| Sheep | 4 | 2010 | 181 | 0.110 |
Why?
|
| Lipids | 3 | 2013 | 315 | 0.110 |
Why?
|
| Genes, env | 2 | 1993 | 16 | 0.110 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2000 | 458 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2005 | 33 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2008 | 542 | 0.110 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1998 | 445 | 0.110 |
Why?
|
| Plasma Cells | 2 | 2005 | 52 | 0.110 |
Why?
|
| Polynucleotide 5'-Hydroxyl-Kinase | 1 | 1994 | 2 | 0.110 |
Why?
|
| Bacteriophage T4 | 1 | 1994 | 7 | 0.110 |
Why?
|
| Endocytosis | 5 | 2015 | 152 | 0.110 |
Why?
|
| RNA Splicing | 1 | 2015 | 162 | 0.110 |
Why?
|
| Encephalitis Virus, Venezuelan Equine | 1 | 2013 | 1 | 0.110 |
Why?
|
| Encephalomyelitis, Venezuelan Equine | 1 | 2013 | 1 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 37 | 0.100 |
Why?
|
| Tetanus Toxoid | 2 | 2012 | 14 | 0.100 |
Why?
|
| Injections, Intravenous | 3 | 2004 | 156 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2000 | 879 | 0.100 |
Why?
|
| Merozoite Surface Protein 1 | 2 | 2004 | 24 | 0.100 |
Why?
|
| Deoxycytosine Nucleotides | 2 | 2005 | 4 | 0.100 |
Why?
|
| Deoxyguanosine | 2 | 2005 | 17 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 92 | 0.100 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1992 | 48 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2013 | 42 | 0.100 |
Why?
|
| Pore Forming Cytotoxic Proteins | 3 | 2009 | 34 | 0.100 |
Why?
|
| Ligands | 4 | 2008 | 416 | 0.100 |
Why?
|
| Gene Expression | 3 | 2008 | 840 | 0.100 |
Why?
|
| Protein Binding | 4 | 2002 | 1603 | 0.100 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 74 | 0.100 |
Why?
|
| DNA, Antisense | 1 | 1993 | 17 | 0.100 |
Why?
|
| Cytosol | 2 | 2013 | 180 | 0.100 |
Why?
|
| Hepatitis B | 2 | 2005 | 32 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2009 | 376 | 0.100 |
Why?
|
| Liver | 2 | 2015 | 860 | 0.100 |
Why?
|
| Virus Shedding | 2 | 2010 | 20 | 0.100 |
Why?
|
| Macaca mulatta | 5 | 2009 | 256 | 0.100 |
Why?
|
| Organophosphorus Compounds | 1 | 1993 | 31 | 0.100 |
Why?
|
| Adolescent | 5 | 2016 | 6260 | 0.100 |
Why?
|
| Administration, Inhalation | 2 | 2006 | 158 | 0.100 |
Why?
|
| DNA Primers | 3 | 2004 | 292 | 0.090 |
Why?
|
| Lymph Nodes | 3 | 2007 | 227 | 0.090 |
Why?
|
| Genes, Viral | 2 | 1989 | 57 | 0.090 |
Why?
|
| Cytomegalovirus Vaccines | 1 | 2012 | 5 | 0.090 |
Why?
|
| Bacterial Infections | 2 | 2006 | 149 | 0.090 |
Why?
|
| Mutation | 4 | 2015 | 2614 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 4 | 2010 | 863 | 0.090 |
Why?
|
| Rats | 4 | 2008 | 1982 | 0.090 |
Why?
|
| Antigens, Ly | 2 | 2002 | 42 | 0.090 |
Why?
|
| Liver Regeneration | 1 | 2011 | 19 | 0.090 |
Why?
|
| Species Specificity | 5 | 2006 | 334 | 0.090 |
Why?
|
| Down-Regulation | 3 | 2004 | 317 | 0.090 |
Why?
|
| Biological Warfare Agents | 1 | 2011 | 2 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2006 | 189 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 66 | 0.090 |
Why?
|
| Caspases | 2 | 2003 | 174 | 0.090 |
Why?
|
| Cell Differentiation | 7 | 2002 | 1350 | 0.090 |
Why?
|
| Immunophenotyping | 4 | 2006 | 196 | 0.090 |
Why?
|
| Child | 3 | 2016 | 4541 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2011 | 22 | 0.090 |
Why?
|
| Hepatectomy | 1 | 2011 | 63 | 0.090 |
Why?
|
| Thymus Gland | 4 | 2001 | 235 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 775 | 0.090 |
Why?
|
| Amino Acid Motifs | 3 | 2011 | 153 | 0.090 |
Why?
|
| Cell Line, Tumor | 6 | 2020 | 1472 | 0.090 |
Why?
|
| Drug Carriers | 1 | 1993 | 179 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 40 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2003 | 105 | 0.080 |
Why?
|
| Virus Diseases | 2 | 2006 | 120 | 0.080 |
Why?
|
| Parainfluenza Virus 3, Bovine | 1 | 2010 | 1 | 0.080 |
Why?
|
| Respirovirus Infections | 1 | 2010 | 6 | 0.080 |
Why?
|
| Neoplasm Transplantation | 7 | 2006 | 166 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 5502 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2011 | 186 | 0.080 |
Why?
|
| NF-KappaB Inhibitor alpha | 3 | 2001 | 27 | 0.080 |
Why?
|
| Retroviridae Infections | 1 | 1990 | 13 | 0.080 |
Why?
|
| Biological Therapy | 1 | 2010 | 16 | 0.080 |
Why?
|
| Kidney Neoplasms | 2 | 2003 | 162 | 0.080 |
Why?
|
| Administration, Intranasal | 3 | 2013 | 27 | 0.080 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2010 | 36 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2000 | 54 | 0.080 |
Why?
|
| Enzyme Activation | 2 | 2002 | 381 | 0.080 |
Why?
|
| Specific Pathogen-Free Organisms | 3 | 2001 | 42 | 0.080 |
Why?
|
| Cell Cycle | 4 | 2002 | 392 | 0.080 |
Why?
|
| HLA-D Antigens | 2 | 2000 | 19 | 0.080 |
Why?
|
| Activating Transcription Factor 2 | 2 | 2000 | 13 | 0.080 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2003 | 46 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 2 | 2002 | 226 | 0.080 |
Why?
|
| Mice, SCID | 5 | 2008 | 517 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2009 | 94 | 0.080 |
Why?
|
| Spleen Focus-Forming Viruses | 1 | 1989 | 1 | 0.080 |
Why?
|
| Virus Inactivation | 1 | 2009 | 2 | 0.080 |
Why?
|
| Protease Inhibitors | 2 | 2008 | 102 | 0.080 |
Why?
|
| Plague Vaccine | 1 | 2009 | 5 | 0.080 |
Why?
|
| Cytotoxicity Tests, Immunologic | 3 | 2008 | 30 | 0.080 |
Why?
|
| SAIDS Vaccines | 1 | 2009 | 22 | 0.080 |
Why?
|
| Plague | 1 | 2009 | 23 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2015 | 690 | 0.070 |
Why?
|
| Young Adult | 2 | 2016 | 4717 | 0.070 |
Why?
|
| B7-1 Antigen | 3 | 2004 | 74 | 0.070 |
Why?
|
| Antibodies, Neoplasm | 2 | 2020 | 26 | 0.070 |
Why?
|
| Nasal Mucosa | 1 | 2008 | 18 | 0.070 |
Why?
|
| Biopolymers | 1 | 2009 | 71 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2011 | 401 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2013 | 145 | 0.070 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2009 | 81 | 0.070 |
Why?
|
| Trinitrobenzenes | 2 | 2005 | 7 | 0.070 |
Why?
|
| Legionella pneumophila | 1 | 2008 | 10 | 0.070 |
Why?
|
| Embolization, Therapeutic | 2 | 2011 | 323 | 0.070 |
Why?
|
| Legionnaires' Disease | 1 | 2008 | 8 | 0.070 |
Why?
|
| Cathepsin K | 1 | 2008 | 7 | 0.070 |
Why?
|
| Bone Marrow Cells | 4 | 2008 | 237 | 0.070 |
Why?
|
| Lymphoid Tissue | 1 | 2008 | 55 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 88 | 0.070 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2008 | 144 | 0.070 |
Why?
|
| Vagina | 2 | 2005 | 83 | 0.070 |
Why?
|
| Quinolines | 1 | 2008 | 45 | 0.070 |
Why?
|
| HIV Antibodies | 1 | 2009 | 146 | 0.070 |
Why?
|
| CD3 Complex | 2 | 2010 | 65 | 0.070 |
Why?
|
| Macrophages, Alveolar | 1 | 2008 | 64 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 1 | 2010 | 262 | 0.070 |
Why?
|
| Hemangiosarcoma | 1 | 2007 | 25 | 0.070 |
Why?
|
| Genes, myc | 2 | 1998 | 18 | 0.070 |
Why?
|
| Klebsiella pneumoniae | 1 | 2007 | 28 | 0.070 |
Why?
|
| Virulence | 2 | 2008 | 193 | 0.070 |
Why?
|
| Blotting, Northern | 4 | 1991 | 150 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2003 | 612 | 0.070 |
Why?
|
| Lysosomes | 1 | 2008 | 166 | 0.070 |
Why?
|
| HMGB1 Protein | 1 | 2006 | 26 | 0.060 |
Why?
|
| Receptors, Interferon | 2 | 2004 | 21 | 0.060 |
Why?
|
| Neutrophils | 2 | 2001 | 376 | 0.060 |
Why?
|
| Endoplasmic Reticulum | 1 | 2008 | 173 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 1 | 2008 | 174 | 0.060 |
Why?
|
| Drosophila Proteins | 2 | 2002 | 688 | 0.060 |
Why?
|
| Respiratory Mucosa | 1 | 2006 | 54 | 0.060 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 12 | 0.060 |
Why?
|
| Vaccines, Subunit | 3 | 2017 | 40 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 171 | 0.060 |
Why?
|
| Receptor, Interferon alpha-beta | 2 | 2004 | 53 | 0.060 |
Why?
|
| Viral Envelope Proteins | 2 | 2002 | 103 | 0.060 |
Why?
|
| Herpesvirus 1, Bovine | 1 | 2006 | 1 | 0.060 |
Why?
|
| Sheep Diseases | 1 | 2006 | 4 | 0.060 |
Why?
|
| CD40 Antigens | 3 | 2001 | 60 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2012 | 515 | 0.060 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 1 | 2005 | 10 | 0.060 |
Why?
|
| Herpesviridae Infections | 1 | 2006 | 27 | 0.060 |
Why?
|
| Aminoquinolines | 1 | 2005 | 16 | 0.060 |
Why?
|
| Antibodies, Antinuclear | 1 | 2005 | 39 | 0.060 |
Why?
|
| Receptors, IgG | 1 | 2005 | 41 | 0.060 |
Why?
|
| Up-Regulation | 5 | 2007 | 373 | 0.060 |
Why?
|
| Hemocyanins | 3 | 2005 | 23 | 0.060 |
Why?
|
| Plasmids | 2 | 2008 | 292 | 0.060 |
Why?
|
| Fetus | 1 | 2005 | 99 | 0.060 |
Why?
|
| Interleukin-4 | 4 | 2002 | 141 | 0.060 |
Why?
|
| Poxviridae Infections | 1 | 2005 | 1 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2004 | 71 | 0.060 |
Why?
|
| Germany | 1 | 2025 | 54 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2003 | 370 | 0.060 |
Why?
|
| Intestinal Perforation | 1 | 2025 | 17 | 0.060 |
Why?
|
| CD40 Ligand | 2 | 2002 | 159 | 0.060 |
Why?
|
| Lung Diseases, Fungal | 1 | 2005 | 35 | 0.060 |
Why?
|
| Topotecan | 2 | 2003 | 5 | 0.060 |
Why?
|
| Sarcoma, Experimental | 1 | 2004 | 6 | 0.060 |
Why?
|
| Myeloid Differentiation Factor 88 | 3 | 2012 | 204 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2004 | 14 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2004 | 71 | 0.060 |
Why?
|
| Heterocyclic Compounds | 1 | 2004 | 12 | 0.050 |
Why?
|
| Interferon-beta | 2 | 2001 | 80 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2003 | 63 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2002 | 99 | 0.050 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2004 | 35 | 0.050 |
Why?
|
| Plasmodium falciparum | 2 | 2004 | 246 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 197 | 0.050 |
Why?
|
| Rheumatoid Factor | 1 | 2004 | 13 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 3 | 1999 | 23 | 0.050 |
Why?
|
| Interferons | 1 | 2004 | 73 | 0.050 |
Why?
|
| Antigen-Antibody Complex | 1 | 2004 | 52 | 0.050 |
Why?
|
| Cryptococcosis | 1 | 2005 | 79 | 0.050 |
Why?
|
| Gastrointestinal Tract | 1 | 2005 | 183 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 166 | 0.050 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2003 | 4 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2023 | 8 | 0.050 |
Why?
|
| Cell Culture Techniques | 2 | 2002 | 182 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2023 | 41 | 0.050 |
Why?
|
| United States | 1 | 2016 | 7868 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 158 | 0.050 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2003 | 11 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 68 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2007 | 738 | 0.050 |
Why?
|
| Animals, Genetically Modified | 1 | 2004 | 299 | 0.050 |
Why?
|
| Skin | 3 | 2007 | 373 | 0.050 |
Why?
|
| Cryptococcus neoformans | 1 | 2005 | 148 | 0.050 |
Why?
|
| Immune Sera | 1 | 2003 | 34 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2004 | 385 | 0.050 |
Why?
|
| Mice, Inbred A | 1 | 2003 | 20 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 239 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 767 | 0.050 |
Why?
|
| Cell Movement | 4 | 2007 | 455 | 0.050 |
Why?
|
| Stereoisomerism | 1 | 2003 | 69 | 0.050 |
Why?
|
| Proto-Oncogenes | 2 | 1999 | 8 | 0.050 |
Why?
|
| Cell Separation | 1 | 2003 | 146 | 0.050 |
Why?
|
| Carmustine | 1 | 2002 | 11 | 0.050 |
Why?
|
| I-kappa B Kinase | 1 | 2003 | 50 | 0.050 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2003 | 82 | 0.050 |
Why?
|
| Phenotype | 3 | 2008 | 1207 | 0.050 |
Why?
|
| Mice, Inbred NZB | 2 | 1994 | 21 | 0.050 |
Why?
|
| Herpesvirus Vaccines | 1 | 2002 | 1 | 0.050 |
Why?
|
| Models, Biological | 1 | 2008 | 1181 | 0.050 |
Why?
|
| Glutathione | 1 | 2002 | 54 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 35 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2025 | 1313 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2022 | 98 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 67 | 0.050 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2002 | 65 | 0.050 |
Why?
|
| Methylation | 2 | 2009 | 129 | 0.050 |
Why?
|
| Binding Sites | 3 | 2001 | 906 | 0.050 |
Why?
|
| Florida | 1 | 2002 | 48 | 0.050 |
Why?
|
| Herpes Simplex | 1 | 2002 | 50 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2001 | 1363 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2013 | 586 | 0.050 |
Why?
|
| Mice, Inbred ICR | 1 | 2001 | 32 | 0.050 |
Why?
|
| Veterinary Medicine | 1 | 2001 | 5 | 0.050 |
Why?
|
| Absorbable Implants | 1 | 2001 | 9 | 0.050 |
Why?
|
| Animals, Laboratory | 1 | 2001 | 6 | 0.050 |
Why?
|
| Bronchial Hyperreactivity | 2 | 1999 | 26 | 0.050 |
Why?
|
| Phagocytosis | 2 | 2003 | 265 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 684 | 0.050 |
Why?
|
| Polyglycolic Acid | 1 | 2001 | 18 | 0.050 |
Why?
|
| Oligonucleotide Probes | 3 | 1990 | 42 | 0.050 |
Why?
|
| Microspheres | 1 | 2001 | 57 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2001 | 31 | 0.050 |
Why?
|
| Herpesvirus 1, Human | 1 | 2002 | 82 | 0.040 |
Why?
|
| Corticosterone | 1 | 2001 | 23 | 0.040 |
Why?
|
| Ovalbumin | 3 | 2008 | 116 | 0.040 |
Why?
|
| Prostaglandins | 1 | 2001 | 18 | 0.040 |
Why?
|
| Uridine | 2 | 2011 | 22 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 123 | 0.040 |
Why?
|
| Malaria, Falciparum | 1 | 2004 | 220 | 0.040 |
Why?
|
| Quality Control | 2 | 2005 | 74 | 0.040 |
Why?
|
| Kidney | 1 | 2004 | 449 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2001 | 76 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2021 | 31 | 0.040 |
Why?
|
| Luciferases | 2 | 2015 | 108 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2007 | 93 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2001 | 139 | 0.040 |
Why?
|
| Ficoll | 1 | 2001 | 4 | 0.040 |
Why?
|
| Length of Stay | 1 | 2025 | 815 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2004 | 314 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 337 | 0.040 |
Why?
|
| Risk Factors | 3 | 2013 | 5367 | 0.040 |
Why?
|
| Immunity | 1 | 2002 | 107 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2021 | 103 | 0.040 |
Why?
|
| Ethanol | 1 | 2004 | 322 | 0.040 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2024 | 237 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 154 | 0.040 |
Why?
|
| Antigens, Surface | 2 | 1993 | 197 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2003 | 517 | 0.040 |
Why?
|
| Ape Diseases | 1 | 2000 | 1 | 0.040 |
Why?
|
| Fluorescein-5-isothiocyanate | 2 | 2003 | 20 | 0.040 |
Why?
|
| Freund's Adjuvant | 2 | 2013 | 14 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2001 | 144 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2025 | 879 | 0.040 |
Why?
|
| Drug Antagonism | 1 | 2000 | 9 | 0.040 |
Why?
|
| Pan troglodytes | 1 | 2000 | 32 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2000 | 48 | 0.040 |
Why?
|
| Brucella abortus | 1 | 1999 | 6 | 0.040 |
Why?
|
| Pregnancy | 2 | 2005 | 2338 | 0.040 |
Why?
|
| bcl-X Protein | 1 | 1999 | 21 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 72 | 0.040 |
Why?
|
| Cell Survival | 2 | 2015 | 576 | 0.040 |
Why?
|
| Concanavalin A | 2 | 1990 | 40 | 0.040 |
Why?
|
| Coculture Techniques | 3 | 2006 | 96 | 0.040 |
Why?
|
| Genes, MHC Class II | 1 | 1999 | 37 | 0.040 |
Why?
|
| Membrane Potentials | 1 | 1999 | 141 | 0.040 |
Why?
|
| Leishmaniasis | 1 | 1999 | 10 | 0.040 |
Why?
|
| Solubility | 3 | 2006 | 180 | 0.040 |
Why?
|
| Macrophages, Peritoneal | 1 | 1999 | 77 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 346 | 0.040 |
Why?
|
| Hepatitis B Antibodies | 1 | 1998 | 9 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 173 | 0.040 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 1998 | 5 | 0.040 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 2 | 2010 | 5 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2007 | 299 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 1998 | 44 | 0.040 |
Why?
|
| Replication Protein C | 1 | 1998 | 6 | 0.040 |
Why?
|
| Antimalarials | 1 | 2000 | 125 | 0.040 |
Why?
|
| Whole-Body Irradiation | 2 | 2004 | 33 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2000 | 238 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 1998 | 35 | 0.040 |
Why?
|
| Protozoan Proteins | 1 | 1999 | 126 | 0.040 |
Why?
|
| Flavonoids | 1 | 1998 | 75 | 0.040 |
Why?
|
| Safety | 1 | 1999 | 145 | 0.040 |
Why?
|
| Transcription Factor RelB | 1 | 1998 | 6 | 0.040 |
Why?
|
| B7-2 Antigen | 3 | 2004 | 32 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 1998 | 16 | 0.040 |
Why?
|
| Cyclophosphamide | 2 | 2003 | 87 | 0.040 |
Why?
|
| Pyridines | 1 | 1998 | 112 | 0.030 |
Why?
|
| Guanosine | 2 | 2006 | 11 | 0.030 |
Why?
|
| Sphingomyelins | 1 | 1997 | 3 | 0.030 |
Why?
|
| Okadaic Acid | 1 | 1997 | 9 | 0.030 |
Why?
|
| Thapsigargin | 1 | 1997 | 17 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 1998 | 81 | 0.030 |
Why?
|
| Monokines | 1 | 1997 | 4 | 0.030 |
Why?
|
| Chemokine CXCL2 | 1 | 1997 | 14 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 1997 | 34 | 0.030 |
Why?
|
| Carrier State | 1 | 1997 | 18 | 0.030 |
Why?
|
| Vitamin K | 1 | 1997 | 16 | 0.030 |
Why?
|
| Chemotactic Factors | 1 | 1997 | 26 | 0.030 |
Why?
|
| Sputum | 1 | 1997 | 42 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1997 | 93 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 1997 | 24 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2017 | 166 | 0.030 |
Why?
|
| Viral Load | 2 | 2009 | 231 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 1997 | 25 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 3304 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 1997 | 54 | 0.030 |
Why?
|
| Virus Replication | 2 | 2005 | 321 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 1996 | 9 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1997 | 102 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1997 | 173 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 1996 | 24 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 1996 | 37 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1997 | 108 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 1999 | 271 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2012 | 1591 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1998 | 324 | 0.030 |
Why?
|
| Mice, Nude | 1 | 1996 | 277 | 0.030 |
Why?
|
| Murine Acquired Immunodeficiency Syndrome | 2 | 1995 | 8 | 0.030 |
Why?
|
| MART-1 Antigen | 2 | 2006 | 8 | 0.030 |
Why?
|
| Epitopes | 2 | 2012 | 290 | 0.030 |
Why?
|
| Heparitin Sulfate | 1 | 2015 | 11 | 0.030 |
Why?
|
| Antibodies | 1 | 1996 | 182 | 0.030 |
Why?
|
| Recurrence | 2 | 2007 | 642 | 0.030 |
Why?
|
| Hemolysis | 1 | 2015 | 40 | 0.030 |
Why?
|
| Aminoethylphosphonic Acid | 1 | 1994 | 1 | 0.030 |
Why?
|
| Polydeoxyribonucleotides | 1 | 1994 | 1 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2008 | 618 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 2 | 2008 | 75 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2008 | 248 | 0.030 |
Why?
|
| Antioxidants | 1 | 1996 | 252 | 0.030 |
Why?
|
| Mice, Mutant Strains | 2 | 1995 | 302 | 0.030 |
Why?
|
| Antibodies, Bacterial | 2 | 2009 | 181 | 0.030 |
Why?
|
| Perforin | 2 | 2006 | 31 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2015 | 149 | 0.030 |
Why?
|
| Nitric Oxide | 2 | 2008 | 174 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1996 | 417 | 0.030 |
Why?
|
| Genes, Reporter | 2 | 2006 | 257 | 0.030 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2013 | 15 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2013 | 10 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 2013 | 52 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2013 | 31 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 2464 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2015 | 536 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2013 | 46 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 67 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 51 | 0.030 |
Why?
|
| Temperature | 1 | 1994 | 307 | 0.030 |
Why?
|
| HLA-A2 Antigen | 2 | 2005 | 64 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1994 | 98 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 1993 | 34 | 0.020 |
Why?
|
| Organophosphates | 1 | 1993 | 16 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 1993 | 46 | 0.020 |
Why?
|
| Molecular Probes | 1 | 1992 | 31 | 0.020 |
Why?
|
| Biological Transport, Active | 2 | 2003 | 37 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2004 | 109 | 0.020 |
Why?
|
| Eosinophilia | 2 | 2005 | 37 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2003 | 12 | 0.020 |
Why?
|
| Zidovudine | 1 | 1992 | 12 | 0.020 |
Why?
|
| Sjogren's Syndrome | 1 | 1992 | 24 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2011 | 6 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 1648 | 0.020 |
Why?
|
| Bilirubin | 1 | 2011 | 18 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2011 | 29 | 0.020 |
Why?
|
| Lectins, C-Type | 2 | 2004 | 89 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2011 | 36 | 0.020 |
Why?
|
| Liver Failure | 1 | 2011 | 18 | 0.020 |
Why?
|
| Antibodies, Protozoan | 2 | 2004 | 52 | 0.020 |
Why?
|
| Portal Vein | 1 | 2011 | 38 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 71 | 0.020 |
Why?
|
| Blood Buffy Coat | 1 | 2011 | 1 | 0.020 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2011 | 10 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 170 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2003 | 401 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2003 | 149 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 1991 | 58 | 0.020 |
Why?
|
| Immunoglobulins | 2 | 2006 | 76 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 1992 | 289 | 0.020 |
Why?
|
| Clone Cells | 2 | 2006 | 114 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 1991 | 54 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 979 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2003 | 489 | 0.020 |
Why?
|
| Enterotoxins | 2 | 2001 | 21 | 0.020 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 1990 | 8 | 0.020 |
Why?
|
| Receptor Cross-Talk | 1 | 2010 | 10 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2010 | 15 | 0.020 |
Why?
|
| Mice, Inbred CBA | 2 | 2000 | 83 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 1991 | 149 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 2010 | 65 | 0.020 |
Why?
|
| Trachea | 1 | 2010 | 85 | 0.020 |
Why?
|
| Biological Transport | 1 | 1991 | 291 | 0.020 |
Why?
|
| Immunologic Memory | 2 | 2002 | 288 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2003 | 307 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 1989 | 106 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 209 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1567 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1992 | 320 | 0.020 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2009 | 2 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 101 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1991 | 263 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1748 | 0.020 |
Why?
|
| Genes, Regulator | 1 | 1989 | 28 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1990 | 206 | 0.020 |
Why?
|
| Disinfectants | 1 | 2009 | 26 | 0.020 |
Why?
|
| Yersinia pestis | 1 | 2009 | 33 | 0.020 |
Why?
|
| Disulfides | 1 | 2009 | 64 | 0.020 |
Why?
|
| Taxoids | 1 | 2008 | 26 | 0.020 |
Why?
|
| Carboplatin | 1 | 2008 | 43 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2008 | 22 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2009 | 222 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2010 | 287 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2008 | 165 | 0.020 |
Why?
|
| Cisplatin | 1 | 2008 | 139 | 0.020 |
Why?
|
| Antigens, CD20 | 1 | 2007 | 14 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 154 | 0.020 |
Why?
|
| Emergency Treatment | 1 | 2007 | 58 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 58 | 0.020 |
Why?
|
| Carrier Proteins | 2 | 2003 | 707 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 1999 | 6694 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2007 | 148 | 0.020 |
Why?
|
| Rituximab | 1 | 2007 | 88 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 116 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 609 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2007 | 99 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 518 | 0.020 |
Why?
|
| Cell-Free System | 1 | 2006 | 31 | 0.020 |
Why?
|
| Body Temperature | 1 | 2006 | 45 | 0.020 |
Why?
|
| DNA Viruses | 1 | 2006 | 17 | 0.020 |
Why?
|
| Haptoglobins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Bystander Effect | 1 | 2006 | 6 | 0.020 |
Why?
|
| Guanine | 1 | 2006 | 23 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 73 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1990 | 627 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 331 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2006 | 85 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 125 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 202 | 0.020 |
Why?
|
| Administration, Intravaginal | 1 | 2005 | 12 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 91 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 2007 | 203 | 0.010 |
Why?
|
| Saponins | 1 | 2005 | 29 | 0.010 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2005 | 33 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 2005 | 14 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 52 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2008 | 1016 | 0.010 |
Why?
|
| Methylcholanthrene | 1 | 2004 | 2 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2006 | 196 | 0.010 |
Why?
|
| Hemagglutinins | 1 | 2004 | 17 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2004 | 59 | 0.010 |
Why?
|
| Interphase | 1 | 2004 | 66 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 2004 | 32 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2005 | 105 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 200 | 0.010 |
Why?
|
| Self Administration | 1 | 2004 | 48 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2004 | 128 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2004 | 138 | 0.010 |
Why?
|
| Aging | 2 | 2001 | 745 | 0.010 |
Why?
|
| Necrosis | 1 | 2004 | 145 | 0.010 |
Why?
|
| Macrolides | 1 | 2004 | 38 | 0.010 |
Why?
|
| Culture Media | 1 | 2004 | 79 | 0.010 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2003 | 9 | 0.010 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2003 | 9 | 0.010 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2003 | 7 | 0.010 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2003 | 8 | 0.010 |
Why?
|
| Gamma Rays | 1 | 2003 | 32 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2004 | 133 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 32 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2004 | 177 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 12 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 2003 | 18 | 0.010 |
Why?
|
| Giant Cells | 1 | 2003 | 15 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2003 | 22 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 507 | 0.010 |
Why?
|
| Cell Count | 1 | 2003 | 133 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2003 | 65 | 0.010 |
Why?
|
| Oils | 1 | 2003 | 71 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 395 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2006 | 1151 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2004 | 325 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 2002 | 57 | 0.010 |
Why?
|
| Receptors, CCR7 | 1 | 2001 | 9 | 0.010 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2001 | 22 | 0.010 |
Why?
|
| Lymphoma, T-Cell | 1 | 2001 | 24 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 33 | 0.010 |
Why?
|
| Piroxicam | 1 | 2001 | 3 | 0.010 |
Why?
|
| Gliotoxin | 1 | 2001 | 5 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 2001 | 11 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2001 | 37 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2001 | 36 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 2001 | 102 | 0.010 |
Why?
|
| Melanoma, Experimental | 1 | 2001 | 44 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2001 | 43 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2001 | 45 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 429 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 2576 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 895 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2002 | 126 | 0.010 |
Why?
|
| Restraint, Physical | 1 | 2001 | 41 | 0.010 |
Why?
|
| Haptens | 1 | 2001 | 13 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2001 | 81 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2001 | 114 | 0.010 |
Why?
|
| Pneumococcal Vaccines | 1 | 2001 | 21 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2001 | 94 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2001 | 126 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2000 | 26 | 0.010 |
Why?
|
| Egg Proteins | 1 | 2000 | 24 | 0.010 |
Why?
|
| Half-Life | 1 | 2000 | 80 | 0.010 |
Why?
|
| Biomarkers | 1 | 2006 | 1410 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 2001 | 66 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2000 | 51 | 0.010 |
Why?
|
| Pongo pygmaeus | 1 | 2000 | 2 | 0.010 |
Why?
|
| Hepatitis Antibodies | 1 | 2000 | 6 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 112 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2001 | 176 | 0.010 |
Why?
|
| Protein Transport | 1 | 2001 | 402 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2001 | 344 | 0.010 |
Why?
|
| Aotidae | 1 | 1999 | 11 | 0.010 |
Why?
|
| Peptide Biosynthesis | 1 | 1999 | 10 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1999 | 35 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 1999 | 37 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2002 | 497 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2001 | 193 | 0.010 |
Why?
|
| Cholera Toxin | 1 | 1999 | 7 | 0.010 |
Why?
|
| Stem Cells | 1 | 2001 | 257 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1999 | 132 | 0.010 |
Why?
|
| Survival Rate | 1 | 2001 | 857 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1999 | 160 | 0.010 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1998 | 5 | 0.010 |
Why?
|
| Langerhans Cells | 1 | 1998 | 11 | 0.010 |
Why?
|
| H-2 Antigens | 1 | 1998 | 67 | 0.010 |
Why?
|
| Bacterial Toxins | 1 | 1999 | 61 | 0.010 |
Why?
|
| Epidermis | 1 | 1998 | 36 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1998 | 21 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2003 | 565 | 0.010 |
Why?
|
| Alum Compounds | 1 | 1998 | 3 | 0.010 |
Why?
|
| Secretory Rate | 1 | 1997 | 10 | 0.010 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1997 | 24 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1997 | 102 | 0.010 |
Why?
|
| Chickens | 1 | 1997 | 95 | 0.010 |
Why?
|
| Proteins | 1 | 2003 | 750 | 0.010 |
Why?
|
| Immunoglobulin Class Switching | 1 | 1998 | 83 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1997 | 83 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1997 | 167 | 0.010 |
Why?
|
| Mitogens | 1 | 1995 | 10 | 0.010 |
Why?
|
| Polyribonucleotides | 1 | 1994 | 2 | 0.010 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1994 | 7 | 0.010 |
Why?
|
| Ribonuclease H | 1 | 1994 | 18 | 0.010 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 1 | 1994 | 5 | 0.010 |
Why?
|
| Blood | 1 | 1994 | 30 | 0.010 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 1994 | 15 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1995 | 134 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1999 | 405 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1994 | 294 | 0.010 |
Why?
|
| Receptors, Interleukin-4 | 1 | 1993 | 8 | 0.010 |
Why?
|
| Thy-1 Antigens | 1 | 1993 | 21 | 0.010 |
Why?
|
| Receptors, Mitogen | 1 | 1993 | 7 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1993 | 21 | 0.010 |
Why?
|
| Leukemia, Experimental | 1 | 1992 | 19 | 0.010 |
Why?
|
| Lupus Nephritis | 1 | 1992 | 37 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1996 | 1667 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1989 | 81 | 0.000 |
Why?
|